Hepatic Steatosis Index at Diagnosis Has the Potential for Forecasting End-stage Kidney Disease in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Overview

Journal J Rheum Dis

Specialty Rheumatology

Date 2023 Sep 22

PMID 37736592

Authors

Hyun Joon Choi

Pil Gyu Park

Yong-Beom Park

Ji Hye Huh

Sang-Won Lee

Ph D

Affiliations

Soon will be listed here.

Abstract

Objective: This study evaluated whether the hepatic steatosis index (HSI) at antineutrophil cytoplasmic antibody-associated vasculitis (AAV) diagnosis could forecast poor outcomes during the disease course in AAV patients.

Methods: This study included 260 AAV patients. The equation for HSI is as follows HSI=8×(alanine aminotransferase/aspartate aminotransferase)+body mass index+(2, diabetes mellitus)+(2, female). The cut-off of HSI was obtained using the receiver operating characteristic curve.

Results: The median age of the 260 patients was 59.5 years, and 65.0% were female. Among the continuous variables excluding the parameters composing the equation for HSI, HSI was significantly correlated with Birmingham vasculitis activity score, five-factor score, haemoglobin, blood urea nitrogen, serum creatinine, and total cholesterol. Among poor outcomes, the area under the curve of HSI for end-stage renal disease (ESRD) was significant, and the cut-off of HSI for ESRD was set at ≤30.82. AAV patients with HSI ≤30.82 exhibited a significantly higher risk of ESRD (relative risk 3.489) and a significantly lower cumulative ESRD-free survival rate than those with HSI >30.82.

Conclusion: This study is the first to demonstrate that HSI at AAV diagnosis could forecast ESRD during the disease course in AAV patients.

References

Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P . The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011; 90(1):19-27. DOI: 10.1097/MD.0b013e318205a4c6. View

Pyo J, Ahn S, Lee L, Choe H, Song J, Park Y . Efficacy of the fibrosis index for predicting end-stage renal disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Int J Clin Pract. 2020; 75(4):e13929. DOI: 10.1111/ijcp.13929. View

Willeke P, Schluter B, Limani A, Becker H, Schotte H . Liver involvement in ANCA-associated vasculitis. Clin Rheumatol. 2015; 35(2):387-94. DOI: 10.1007/s10067-015-2882-5. View

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W . Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2006; 66(2):222-7. PMC: 1798520. DOI: 10.1136/ard.2006.054593. View

Weng C, Liu Z . Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Chin Med J (Engl). 2019; 132(23):2848-2855. PMC: 6940077. DOI: 10.1097/CM9.0000000000000539. View

Toraman A, Gunduz O . Predictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: Our single-center, tertiary care experience. Arch Rheumatol. 2021; 36(3):445-457. PMC: 8612491. DOI: 10.46497/ArchRheumatol.2021.8687. View

Pyo J, Ahn S, Lee L, Choi G, Song J, Park Y . The novel fibrosis index at diagnosis may predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis without substantial liver diseases. Clinics (Sao Paulo). 2021; 76:e2501. PMC: 8009064. DOI: 10.6061/clinics/2021/e2501. View

Guo Q, Yu L, Zhang X, Shang J, Duan X . Analysis of the risk factors for end‑stage renal disease and mortality in ANCA-associated vasculitis: a study from a single center of the Chinese Rheumatism Data Center. Clin Rheumatol. 2022; 42(2):489-499. DOI: 10.1007/s10067-022-06419-1. View

Pyo J, Ahn S, Song J, Park Y, Lee S . Application of the 2022 ACR/EULAR criteria for microscopic polyangiitis to patients with previously diagnosed microscopic polyangiitis. Clin Exp Rheumatol. 2022; 41(4):792-799. DOI: 10.55563/clinexprheumatol/vmrk76. View

10.

Musso G, Cassader M, Cohney S, De Michieli F, Pinach S, Saba F . Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care. 2016; 39(10):1830-45. DOI: 10.2337/dc15-1182. View

11.

Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F . 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012; 65(1):1-11. DOI: 10.1002/art.37715. View

12.

Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C . Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes. Int J Med Sci. 2021; 18(14):3280-3289. PMC: 8364463. DOI: 10.7150/ijms.62010. View

13.

McAdoo S, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J . Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2018; 34(1):63-73. PMC: 6322443. DOI: 10.1093/ndt/gfx378. View

14.

Pyo J, Ahn S, Song J, Park Y, Lee S . The Reclassification of Patients With Previously Diagnosed Eosinophilic Granulomatosis With Polyangiitis Based on the 2022 ACR/EULAR Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. J Rheumatol. 2022; 50(2):213-218. DOI: 10.3899/jrheum.220560. View

15.

Ochiai H, Shirasawa T, Yoshimoto T, Nagahama S, Sakamoto K, Azuma M . Hepatic Steatosis Index and Chronic Kidney Disease among Middle-Aged Individuals: A Large-Scale Study in Japan. Dis Markers. 2021; 2021:9941834. PMC: 8211514. DOI: 10.1155/2021/9941834. View

16.

Pyo J, Ahn S, Song J, Park Y, Lee S . Reclassification of previously diagnosed GPA patients using the 2022 ACR/EULAR classification criteria. Rheumatology (Oxford). 2022; 62(3):1179-1186. DOI: 10.1093/rheumatology/keac267. View

17.

Xu L, Lu W, Li P, Shen F, Mi Y, Fan J . A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Dig Liver Dis. 2017; 49(8):910-917. DOI: 10.1016/j.dld.2017.03.013. View

18.

Park H, Park J, Jung S, Song J, Park Y, Lee S . Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. BMC Gastroenterol. 2019; 19(1):90. PMC: 6567497. DOI: 10.1186/s12876-019-1007-z. View

19.

Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J . Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 2017; 33(1):270-276. DOI: 10.1111/jgh.13814. View

20.

Bhamra K, Luqmani R . Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012; 14(6):494-500. DOI: 10.1007/s11926-012-0291-1. View